Physician profile
Arvind C Reddy
NPI 1366557886
$4,034.47
in general payments reported to CMS, 2019-2025
23 companies · $836 in 2025
The $836 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $189 · 2021: $306 · 2022: $279 · 2023: $923 · 2024: $1,238 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,997.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,996.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,201.43 | 2019-2025 | |
| Medtronic, INC. | $522.76 | 2021-2024 | Endoflip, Bravo, Gi Genius |
| Endogastric Solutions, INC | $362.43 | 2022-2024 | Esophyx |
| Qol Medical, LLC | $277.29 | 2024-2025 | Sucraid, Sucraid |
| Boston Scientific Corporation | $275.00 | 2021-2024 | Exalt Model D |
| Intuitive Surgical, INC. | $184.44 | 2023 | Da Vinci Surgical System |
| Ipsen Biopharmaceuticals, INC | $139.15 | 2025 | Iqirvo |
| Novo Nordisk INC | $121.86 | 2023 | Wegovy |
| Merit Medical Systems INC | $120.30 | 2024 | |
| Madrigal Pharmaceuticals | $118.24 | 2025 | Rezdiffra |
| Conmed Corporation | $106.48 | 2020-2023 | Airseal |
| Gilead Sciences, INC. | $96.44 | 2019-2020 | |
| Axonics, INC. | $73.85 | 2023 | Axonics |
| Phathom Pharmaceuticals, INC. | $70.24 | 2024-2025 | Voquezna |
| Celgene Corporation | $66.05 | 2022-2024 | Zeposia |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $62.50 | 2023 | Arista Ah Flexitip |
| Takeda Pharmaceuticals U.S.A., INC. | $57.04 | 2019-2024 | Entyvio |
| Nestle Healthcare Nutrition INC. | $54.39 | 2021-2023 | |
| Covidien Lp | $50.06 | 2020 | |
| Ferring Pharmaceuticals INC. | $21.63 | 2023 | Rebyota |
| Endo Pharmaceuticals INC. | $19.58 | 2019 | |
| Ironwood Pharmaceuticals, INC | $17.87 | 2023 | Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arvind Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.